Bellevue Asset Management, LLC Ascendis Pharma A/S Transaction History
Bellevue Asset Management, LLC
- $208 Million
- Q3 2025
A detailed history of Bellevue Asset Management, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Bellevue Asset Management, LLC holds 11 shares of ASND stock, worth $2,248. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11
Previous 19
42.11%
Holding current value
$2,248
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ASND
# of Institutions
318Shares Held
65MCall Options Held
476KPut Options Held
142K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...